Ardelyx, Inc. (NASDAQ:ARDX) Stock Has Consensus Target Price of $13.90 According to Analysts

26 Sep 2026, 01:58 by Doug Wharley · The Cerbat Gem

Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the twelve research firms that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $13.90.

A number of research firms recently issued reports on ARDX. BTIG Research lowered their price target on Ardelyx from $17.00 to $14.00 and set a “buy” rating on the stock in a report on Friday, August 7th. Zacks Research lowered shares of Ardelyx from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 22nd. HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of Ardelyx in a research report on Friday, August 7th. Citigroup dropped their price objective on shares of Ardelyx from $14.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Finally, Wedbush reissued an “outperform” rating and set a $9.00 price target on shares of Ardelyx in a report on Tuesday, August 18th.

View Our Latest Stock Report on Ardelyx

Trending Headlines about Ardelyx

Here are the key news stories impacting Ardelyx this week:

Neutral Sentiment: Reported short interest was listed at zero shares as of September 24, producing a 0.0-day short-interest ratio. This suggests short selling is not currently a significant identifiable driver, although the figure may reflect a reporting anomaly.
Negative Sentiment: Multiple firms—including Robbins LLP, Bronstein Gewirtz & Grossman, SBS Law, Rosen Law Firm, Pomerantz, Portnoy Law Firm, Kaplan Fox and SueWallSt—announced or reiterated a securities class action involving Ardelyx investors who purchased shares from January 13, 2025, through August 6, 2026. Investors have until November 16, 2026 to seek appointment as lead plaintiff. Robbins LLP class action reminder Bronstein Gewirtz & Grossman class action notice
Negative Sentiment: The complaint reportedly alleges that Ardelyx and certain executives misled investors about commercial performance and growth, including whether the company’s patient-access strategy was effective. The allegations reference payer prior-authorization and step-edit requirements that allegedly restricted prescriptions for IBSRELA and XPHOZAH. These claims have not been proven, but the repeated notices increase legal, reputational and potential financial-risk concerns for shareholders. Rosen Law Firm investor notice SueWallSt lawsuit notice

Ardelyx Stock Down 0.9%

Shares of NASDAQ:ARDX opened at $3.42 on Wednesday. Ardelyx has a 1-year low of $3.33 and a 1-year high of $8.40. The company has a debt-to-equity ratio of 1.69, a current ratio of 3.34 and a quick ratio of 3.15. The stock has a market cap of $852.23 million, a P/E ratio of -15.55 and a beta of 0.70. The firm has a fifty day moving average price of $4.10 and a 200 day moving average price of $5.26.

Ardelyx (NASDAQ:ARDX – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). Ardelyx had a negative net margin of 12.35% and a negative return on equity of 36.00%. The business had revenue of $120.88 million during the quarter, compared to analyst estimates of $121.03 million. During the same quarter in the prior year, the firm posted ($0.08) earnings per share. The company’s revenue for the quarter was up 34.3% compared to the same quarter last year. Sell-side analysts predict that Ardelyx will post -0.2 EPS for the current year.

Insider Activity at Ardelyx

In related news, insider James Brady sold 15,136 shares of Ardelyx stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $3.86, for a total value of $58,424.96. Following the sale, the insider directly owned 245,930 shares in the company, valued at $949,289.80. The trade was a 5.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider John E. Bishop sold 19,750 shares of the company’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $3.86, for a total value of $76,235.00. Following the transaction, the insider directly owned 317,095 shares in the company, valued at $1,223,986.70. This represents a 5.86% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 126,059 shares of company stock worth $486,588 in the last three months. 5.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Ardelyx

Several institutional investors have recently made changes to their positions in ARDX. Principal Financial Group Inc. lifted its position in shares of Ardelyx by 22.7% during the 1st quarter. Principal Financial Group Inc. now owns 17,570 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 3,253 shares during the period. NewEdge Advisors LLC grew its holdings in shares of Ardelyx by 30.0% in the 2nd quarter. NewEdge Advisors LLC now owns 23,724 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 5,476 shares during the period. ProShare Advisors LLC grew its holdings in shares of Ardelyx by 11.4% in the 4th quarter. ProShare Advisors LLC now owns 54,531 shares of the biopharmaceutical company’s stock worth $318,000 after acquiring an additional 5,595 shares during the period. Swiss National Bank increased its stake in Ardelyx by 1.2% in the 1st quarter. Swiss National Bank now owns 480,800 shares of the biopharmaceutical company’s stock valued at $2,880,000 after purchasing an additional 5,600 shares in the last quarter. Finally, Hsbc Holdings PLC increased its stake in Ardelyx by 7.0% in the 2nd quarter. Hsbc Holdings PLC now owns 100,550 shares of the biopharmaceutical company’s stock valued at $509,000 after purchasing an additional 6,619 shares in the last quarter. 58.92% of the stock is currently owned by hedge funds and other institutional investors.

About Ardelyx

(Get Free Report)

Ardelyx, Inc is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal conditions. The company’s lead product candidates and marketed medicines are designed to address disorders involving the regulation of phosphate and other substances in the digestive system.